Health

FDA Panel Reviews Peptide Controversies

Updated 2026-07-23 15:10 UTC 1 source Neutral

The FDA is considering the fate of peptides, with approvals for RevMed and GSK, as well as data on Lilly's 'triple-G.' The panel is weighing these developments.

Coverage timeline — 1 article

STAT News

FDA panel confronting peptide controversy

Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."

2026-07-23 14:58 UTC